Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan
· Delayed Price · Currency is TWD 220.50
-3.50 (-1.56%)
Apr 29, 2026, 1:30 PM CST
Lotus Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 20,509 | 18,584 | 16,958 | 14,633 | 12,649 | Upgrade
|
| Revenue Growth (YoY) | 10.36% | 9.59% | 15.89% | 15.68% | 17.90% | Upgrade
|
| Cost of Revenue | 8,603 | 7,660 | 7,574 | 6,827 | 7,009 | Upgrade
|
| Gross Profit | 11,907 | 10,924 | 9,384 | 7,806 | 5,640 | Upgrade
|
| Selling, General & Admin | 4,983 | 4,133 | 3,764 | 3,141 | 2,703 | Upgrade
|
| Research & Development | 724.31 | 613.9 | 541.46 | 419.01 | 373.84 | Upgrade
|
| Operating Expenses | 5,700 | 4,744 | 4,302 | 3,557 | 3,112 | Upgrade
|
| Operating Income | 6,207 | 6,180 | 5,082 | 4,249 | 2,529 | Upgrade
|
| Interest Expense | -877.68 | -561.39 | -533.69 | -356.22 | -266.69 | Upgrade
|
| Interest & Investment Income | 114.51 | 101.44 | 31.55 | 3.51 | 5.34 | Upgrade
|
| Currency Exchange Gain (Loss) | 16.78 | 168.11 | 91.67 | -81.22 | -119.23 | Upgrade
|
| Other Non Operating Income (Expenses) | 95.54 | 28.89 | 23.94 | -10.31 | 1.78 | Upgrade
|
| EBT Excluding Unusual Items | 5,556 | 5,917 | 4,696 | 3,805 | 2,150 | Upgrade
|
| Gain (Loss) on Sale of Investments | 548.28 | 604.16 | 715.05 | 286.81 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -13.72 | -0.7 | -24.75 | 2.52 | -3.2 | Upgrade
|
| Asset Writedown | -303.02 | -159.99 | -179.37 | -138.26 | -233.18 | Upgrade
|
| Other Unusual Items | -69.45 | -0.91 | -103.79 | -16 | -43.42 | Upgrade
|
| Pretax Income | 5,718 | 6,360 | 5,103 | 3,940 | 1,870 | Upgrade
|
| Income Tax Expense | 998.12 | 1,294 | 997.3 | 919.46 | 466.65 | Upgrade
|
| Earnings From Continuing Operations | 4,720 | 5,066 | 4,106 | 3,021 | 1,403 | Upgrade
|
| Net Income | 4,720 | 5,066 | 4,106 | 3,021 | 1,403 | Upgrade
|
| Net Income to Common | 4,720 | 5,066 | 4,106 | 3,021 | 1,403 | Upgrade
|
| Net Income Growth | -6.82% | 23.38% | 35.91% | 115.25% | 36.68% | Upgrade
|
| Shares Outstanding (Basic) | 260 | 262 | 261 | 261 | 255 | Upgrade
|
| Shares Outstanding (Diluted) | 262 | 263 | 262 | 262 | 257 | Upgrade
|
| Shares Change (YoY) | -0.67% | 0.53% | 0.13% | 1.95% | 5.43% | Upgrade
|
| EPS (Basic) | 18.14 | 19.35 | 15.72 | 11.59 | 5.50 | Upgrade
|
| EPS (Diluted) | 18.04 | 19.23 | 15.67 | 11.54 | 5.47 | Upgrade
|
| EPS Growth | -6.19% | 22.72% | 35.79% | 110.97% | 29.62% | Upgrade
|
| Free Cash Flow | 6,162 | 5,801 | 1,204 | 3,142 | -453.07 | Upgrade
|
| Free Cash Flow Per Share | 23.55 | 22.02 | 4.59 | 12.01 | -1.76 | Upgrade
|
| Dividend Per Share | 2.560 | 5.730 | 4.660 | 3.460 | 1.930 | Upgrade
|
| Dividend Growth | -55.32% | 22.96% | 34.68% | 79.27% | 451.43% | Upgrade
|
| Gross Margin | 58.05% | 58.78% | 55.34% | 53.35% | 44.59% | Upgrade
|
| Operating Margin | 30.26% | 33.25% | 29.97% | 29.04% | 19.99% | Upgrade
|
| Profit Margin | 23.01% | 27.26% | 24.21% | 20.64% | 11.09% | Upgrade
|
| Free Cash Flow Margin | 30.05% | 31.21% | 7.10% | 21.47% | -3.58% | Upgrade
|
| EBITDA | 7,609 | 7,331 | 6,171 | 5,094 | 3,204 | Upgrade
|
| EBITDA Margin | 37.10% | 39.45% | 36.39% | 34.81% | 25.33% | Upgrade
|
| D&A For EBITDA | 1,402 | 1,151 | 1,088 | 844.44 | 675.77 | Upgrade
|
| EBIT | 6,207 | 6,180 | 5,082 | 4,249 | 2,529 | Upgrade
|
| EBIT Margin | 30.26% | 33.25% | 29.97% | 29.04% | 19.99% | Upgrade
|
| Effective Tax Rate | 17.46% | 20.35% | 19.54% | 23.34% | 24.95% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.